{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:31:11Z","timestamp":1785879071698,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Rheumatoid arthritis (RA) and osteoarthritis (OA) are prevalent chronic joint diseases characterized by persistent inflammation, progressive cartilage degeneration, and impaired tissue repair mechanisms. While inflammatory pathways have been extensively studied, increasing attention has been directed toward the failure of inflammation resolution as a key contributor to chronic joint pathology. Specialized pro-resolving mediators (SPMs), including Maresin-1 (MaR1), play an active role in terminating inflammation and promoting tissue homeostasis. However, the relationship between MaR1 and cartilage-specific biomarkers such as Cartilage Oligomeric Matrix Protein (COMP) and Wnt1-inducible signaling pathway protein-1 (WISP-1) has not been sufficiently elucidated. This study investigated circulating MaR1 levels in RA and OA and examined their associations with serum COMP and WISP-1 as well as clinical inflammatory parameters. This cross-sectional, biomarker-based study included a total of 150 participants, comprising 50 patients with RA, 50 patients with OA, and 50 sex-matched healthy controls. Serum levels of MaR1, COMP, and WISP-1 were measured using enzyme-linked immunosorbent assay (ELISA). Demographic characteristics and inflammatory parameters, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and rheumatoid factor (RF), were recorded. Intergroup comparisons were performed using one-way analysis of variance (ANOVA) followed by appropriate post-hoc tests. Serum MaR1 levels were significantly reduced in both RA (44.1\u2009\u00b1\u20092.2 ng\/L) and OA (42.2\u2009\u00b1\u20093.2 ng\/L) compared with controls (78.5\u2009\u00b1\u20097.5 ng\/L;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). COMP levels were significantly lower in the RA group than in the OA and control groups (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05 and\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001, respectively). Similarly, WISP-1 concentrations were decreased in both RA and OA compared with healthy controls (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). The marked reduction in MaR1 levels in RA and OA is consistent with altered inflammation-resolution biology. Concurrent decreases in COMP and WISP-1 may reflect changes in cartilage remodeling dynamics. Overall, MaR1 appears to be a candidate biomarker associated with inflammation-resolution pathways in arthritic diseases.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-42927-9","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:35:52Z","timestamp":1773812152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Circulating Maresin-1 and cartilage remodeling biomarkers in rheumatoid arthritis and osteoarthritis"],"prefix":"10.1038","volume":"16","author":[{"given":"Omer","family":"Esmez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulnihal","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubeyde","family":"Ercan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Secil","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem Sedef","family":"Dogru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Karatas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"23","key":"42927_CR1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N Engl. J. Med. 365(23), 2205\u20132219 (2011).","journal-title":"N Engl. J. Med."},{"issue":"11","key":"42927_CR2","first-page":"1799","volume":"12","author":"JA Braaten","year":"2022","unstructured":"Braaten, J. A. et al. Biomarkers for osteoarthritis diseases. Life (Basel). 12(11), 1799 (2022).","journal-title":"Life (Basel)"},{"issue":"1","key":"42927_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1084\/jem.20081880","volume":"206","author":"CN Serhan","year":"2009","unstructured":"Serhan, C. N. et al. Maresins: novel macrophage mediators with potent anti-inflammatory and pro-resolving actions. J. Exp. Med. 206(1), 15\u201323 (2009).","journal-title":"J. Exp. Med."},{"issue":"46","key":"42927_CR4","doi-asserted-by":"publisher","first-page":"16526","DOI":"10.1073\/pnas.1407123111","volume":"111","author":"RE Abdulnour","year":"2014","unstructured":"Abdulnour, R. E. et al. Maresin 1 biosynthesis during platelet\u2013neutrophil interactions is organ-protective. Proc. Natl. Acad. Sci. U S A. 111(46), 16526\u201316531 (2014).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"7","key":"42927_CR5","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1172\/JCI97943","volume":"128","author":"CN Serhan","year":"2018","unstructured":"Serhan, C. N. & Levy, B. D. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J. Clin. Invest. 128(7), 2657\u20132669 (2018).","journal-title":"J. Clin. Invest."},{"issue":"3","key":"42927_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3390\/ijms23031367","volume":"23","author":"N Saito-Sasaki","year":"2022","unstructured":"Saito-Sasaki, N., Sawada, Y. & Nakamura, M. Maresin-1 and inflammatory disease. Int. J. Mol. Sci. 23(3), 1367 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"42927_CR7","doi-asserted-by":"publisher","first-page":"11012","DOI":"10.3390\/ijms241311012","volume":"24","author":"WC Liu","year":"2023","unstructured":"Liu, W. C., Yang, Y. H., Wang, Y. C., Chang, W. M. & Wang, C. W. Maresin: macrophage mediator for resolving inflammation and bridging tissue regeneration\u2014a system-based preclinical systematic review. Int. J. Mol. Sci. 24(13), 11012 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"42927_CR8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1080\/03008207.2020.1780218","volume":"62","author":"J Lu","year":"2021","unstructured":"Lu, J. et al. Maresin-1 suppresses IL-1\u03b2-induced MMP-13 secretion by activating the PI3K\/AKT pathway and inhibiting the NF-\u03baB pathway in synovioblasts of an osteoarthritis rat model with treadmill exercise. Connect. Tissue Res. 62(5), 508\u2013518 (2021).","journal-title":"Connect. Tissue Res."},{"issue":"46","key":"42927_CR9","doi-asserted-by":"publisher","first-page":"13821","DOI":"10.1021\/acs.jafc.1c05819","volume":"69","author":"G Yang","year":"2021","unstructured":"Yang, G. et al. Pterostilbene coupled with physical exercise effectively mitigates collagen-induced articular synovial inflammation by correcting the PI3K\/AKT\/NF-\u03baB pathway. J. Agric. Food Chem. 69(46), 13821\u201313830 (2021).","journal-title":"J. Agric. Food Chem."},{"key":"42927_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4137\/BMI.S645","volume":"4","author":"S Tseng","year":"2009","unstructured":"Tseng, S., Reddi, A. H. & Di Cesare, P. E. Cartilage oligomeric matrix protein (COMP): a biomarker of arthritis. Biomark. Insights. 4, 65\u201370 (2009).","journal-title":"Biomark. Insights"},{"issue":"1","key":"42927_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/1471-2474-14-229","volume":"14","author":"ML Andersson","year":"2013","unstructured":"Andersson, M. L. et al. Early increase in serum COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis. BMC Musculoskelet. Disord. 14(1), 229 (2013).","journal-title":"BMC Musculoskelet. Disord"},{"issue":"12","key":"42927_CR12","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.19082\/5940","volume":"9","author":"M Saghafi","year":"2017","unstructured":"Saghafi, M. et al. Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity. Electron. Physician. 9(12), 5940 (2017). (Sayfa aral\u0131\u011f\u0131 kontrol \u00f6nerilir.).","journal-title":"Electron. Physician"},{"issue":"1","key":"42927_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12967-024-05364-8","volume":"22","author":"K Singh","year":"2024","unstructured":"Singh, K. & Oladipupo, S. S. An overview of CCN4 (WISP1) role in human diseases. J. Transl Med. 22(1), 601 (2024).","journal-title":"J. Transl Med."},{"issue":"6","key":"42927_CR14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/rheumatology\/key426","volume":"58","author":"MH van den Bosch","year":"2019","unstructured":"van den Bosch, M. H. et al. Increased WISP1 expression in human osteoarthritic articular cartilage is epigenetically regulated and decreases cartilage matrix production. Rheumatol. (Oxford). 58(6), 1065\u20131074 (2019).","journal-title":"Rheumatol. (Oxford)"},{"key":"42927_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.molimm.2025.02.004","volume":"179","author":"T Hao","year":"2025","unstructured":"Hao, T. et al. WISP1 promotes the progression of rheumatoid arthritis through NLRP3 inflammasome activation. Mol. Immunol. 179, 106\u2013115 (2025).","journal-title":"Mol. Immunol."},{"issue":"2","key":"42927_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul, F., Erdfelder, E., Lang, A. G. & Buchner, A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods. 39(2), 175\u2013191 (2007).","journal-title":"Behav. Res. Methods"},{"issue":"1","key":"42927_CR17","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/s41467-020-19176-z","volume":"11","author":"EA Gomez","year":"2020","unstructured":"Gomez, E. A. et al. Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis. Nat. Commun. 11(1), 5420 (2020).","journal-title":"Nat. Commun."},{"issue":"2","key":"42927_CR18","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.5415\/apallergy.2020.10.e21","volume":"10","author":"Y Sano","year":"2020","unstructured":"Sano, Y. et al. Activation of inflammation and resolution pathways of lipid mediators in synovial fluid from patients with severe rheumatoid arthritis compared with severe osteoarthritis. Asia Pac. Allergy. 10(2), e21 (2020).","journal-title":"Asia Pac. Allergy"},{"key":"42927_CR19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/annrheumdis-2022-eular.692","volume":"81","author":"M Alotaibi","year":"2022","unstructured":"Alotaibi, M. et al. Different bioactive lipid profiles predict response to TNF or IL-6 inhibitors in rheumatoid arthritis: result of the CorEvitas CERTAIN comparative effectiveness study. Ann. Rheum. Dis. 81, 508 (2022). (Tam sayfa\/supplement bilgisi kontrol \u00f6nerilir.).","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"42927_CR20","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1136\/annrheumdis-2018-213511","volume":"77","author":"S Jin","year":"2018","unstructured":"Jin, S. et al. Maresin 1 improves the Treg\/Th17 imbalance in rheumatoid arthritis through miR-21. Ann. Rheum. Dis. 77(11), 1644\u20131652 (2018).","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"42927_CR21","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1111\/bph.14647","volume":"176","author":"V Fattori","year":"2019","unstructured":"Fattori, V. et al. The specialised pro-resolving lipid mediator maresin 1 reduces inflammatory pain with a long-lasting analgesic effect. Br. J. Pharmacol. 176(11), 1728\u20131744 (2019).","journal-title":"Br. J. Pharmacol."},{"key":"42927_CR22","doi-asserted-by":"publisher","first-page":"6680456","DOI":"10.1155\/2021\/6680456","volume":"2021","author":"Y Lu","year":"2021","unstructured":"Lu, Y. et al. The proresolving lipid mediator maresin 1 alleviates experimental pancreatitis via switching macrophage polarization. Mediators Inflamm. 2021, 6680456 (2021).","journal-title":"Mediators Inflamm."},{"key":"42927_CR23","doi-asserted-by":"publisher","first-page":"116153","DOI":"10.1016\/j.biopha.2024.116153","volume":"171","author":"Y Su","year":"2024","unstructured":"Su, Y. et al. Lipid mediators obtained from docosahexaenoic acid by soybean lipoxygenase attenuate RANKL-induced osteoclast differentiation and rheumatoid arthritis. Biomed. Pharmacother. 171, 116153 (2024).","journal-title":"Biomed. Pharmacother"},{"issue":"16","key":"42927_CR24","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.3390\/jcm12165185","volume":"12","author":"A Szeremeta","year":"2023","unstructured":"Szeremeta, A., Jura-P\u00f3\u0142torak, A., Zo\u0144-Giebel, A., Olczyk, K. & Komosi\u0144ska-Vassev, K. Effects of etanercept and adalimumab on serum levels of cartilage remodeling markers in women with rheumatoid arthritis. J. Clin. Med. 12(16), 5185 (2023).","journal-title":"J. Clin. Med."},{"issue":"11","key":"42927_CR25","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.joca.2017.07.012","volume":"25","author":"M van den Bosch","year":"2017","unstructured":"van den Bosch, M. et al. WISP1\/CCN4 aggravates cartilage degeneration in experimental osteoarthritis. Osteoarthr. Cartil. 25(11), 1900\u20131911 (2017).","journal-title":"Osteoarthr. Cartil."},{"issue":"5","key":"42927_CR26","doi-asserted-by":"publisher","first-page":"e85922","DOI":"10.1172\/jci.insight.85922","volume":"1","author":"LV Norling","year":"2016","unstructured":"Norling, L. V. et al. Pro-resolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight. 1(5), e85922 (2016).","journal-title":"JCI Insight"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42927-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42927-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42927-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:24:35Z","timestamp":1777591475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42927-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42927"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42927-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the F\u0131rat University Non-Interventional Research Ethics Committee (Session No: 2025\/11\u201318, Date: August 21, 2025; Chair: Prof. Dr. Mustafa Kaplan). Written informed consent was obtained from all participants prior to enrollment. All procedures were performed in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"13975"}}